The binding of programmed death-1 (PD-1) on the surface of T cells and PD-1 ligand 1 (PD-
L1) on tumor cells can prevent the immune-killing effect of T cells on tumor cells and …

Introduction Survival rates for early-stage non-small cell lung cancer (NSCLC) remain poor
despite the decade-long established standard of surgical resection and systemic adjuvant …

Background To develop a radiomics model based on chest computed tomography (CT) for
the prediction of a pathological complete response (pCR) after neoadjuvant or conversion …

Background There is no standard consensus on the optimal number of cycles of
neoadjuvant immunotherapy prior to surgery for patients with locoregionally advanced non …

Neoadjuvant therapy with immune checkpoint inhibitors in ope... : Current Opinion in Oncology
Neoadjuvant therapy with immune checkpoint inhibitors in operable nonsmall cell lung cancer …

In the open‐label, phase III CheckMate 816 study (NCT02998528), neoadjuvant nivolumab
plus chemotherapy demonstrated statistically significant improvements in event‐free survival …

Cabozantinib is an oral multikinase inhibitor approved for treatment in metastatic renal cell
carcinoma (RCC). We hypothesized that neoadjuvant cabozantinib could downstage …

Simple Summary Lung cancer treatment often involves surgical resection. Traditional
resection involves a large thoracotomy incision to access the chest cavity. However …

The role of immunotherapy as systemic therapy for non-metastatic non-small cell lung
cancer (NSCLC) has evolved rapidly over the last decade. There are several well-conducted …

Background: Lung cancer is a leading cause of cancer deaths in the United States. An
increasing understanding of relevant non-small cell lung cancer (NSCLC) biomarkers has …